RedHill Biopharma (RDHL) Raw Materials (2018 - 2024)

RedHill Biopharma (RDHL) has 7 years of Raw Materials data on file, last reported at $513000.0 in Q4 2024.

• Raw Materials for Q4 2024 came in at $513000.0, down 38.04% year-over-year; the trailing twelve-month figure through Dec 2024 was $513000.0 (down 38.04% YoY), and the FY2024 annual result was $513000.0, down 38.04% from the prior year.
• Raw Materials fell to $513000.0 in Q4 2024 per RDHL's latest filing, from $828000.0 in the prior quarter.
• Over five years, Raw Materials peaked at $3.0 million in Q4 2021 and troughed at $513000.0 in Q4 2024.
• A 5-year average of $1.6 million and a median of $1.8 million in 2020 frame the typical range for Raw Materials.
• The sharpest annual moves came in 2021 and 2023: Raw Materials jumped 68.08% in 2021, then tumbled 53.92% in 2023.
• A 5-year view of Raw Materials shows it stood at $1.8 million in 2020, then jumped by 68.08% to $3.0 million in 2021, then sank by 40.34% to $1.8 million in 2022, then sank by 53.92% to $828000.0 in 2023, then slumped by 38.04% to $513000.0 in 2024.
• Business Quant data shows RDHL's Raw Materials at $513000.0 in Q4 2024, $828000.0 in Q4 2023, and $1.8 million in Q4 2022.